KR20210125037A - 타우 인식 항체 - Google Patents

타우 인식 항체 Download PDF

Info

Publication number
KR20210125037A
KR20210125037A KR1020217028112A KR20217028112A KR20210125037A KR 20210125037 A KR20210125037 A KR 20210125037A KR 1020217028112 A KR1020217028112 A KR 1020217028112A KR 20217028112 A KR20217028112 A KR 20217028112A KR 20210125037 A KR20210125037 A KR 20210125037A
Authority
KR
South Korea
Prior art keywords
seq
occupied
amino acid
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217028112A
Other languages
English (en)
Korean (ko)
Inventor
3세 필립 제임스 돌란
탈로찬 에스. 니자르
스베틀라나 알렉산더
로빈 바버
스티븐 제드 탐
Original Assignee
프로테나 바이오사이언시즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로테나 바이오사이언시즈 리미티드 filed Critical 프로테나 바이오사이언시즈 리미티드
Publication of KR20210125037A publication Critical patent/KR20210125037A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217028112A 2019-02-08 2020-02-07 타우 인식 항체 Pending KR20210125037A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962803334P 2019-02-08 2019-02-08
US62/803,334 2019-02-08
US201962813124P 2019-03-03 2019-03-03
US62/813,124 2019-03-03
US201962855434P 2019-05-31 2019-05-31
US62/855,434 2019-05-31
PCT/US2020/017357 WO2020163817A1 (en) 2019-02-08 2020-02-07 Antibodies recognizing tau

Publications (1)

Publication Number Publication Date
KR20210125037A true KR20210125037A (ko) 2021-10-15

Family

ID=71947192

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217028112A Pending KR20210125037A (ko) 2019-02-08 2020-02-07 타우 인식 항체

Country Status (14)

Country Link
US (1) US20220275067A1 (https=)
EP (1) EP3921343A4 (https=)
JP (2) JP7681316B2 (https=)
KR (1) KR20210125037A (https=)
CN (2) CN113597431B (https=)
AU (1) AU2020219374A1 (https=)
BR (1) BR112021015501A2 (https=)
CA (1) CA3128392A1 (https=)
CO (1) CO2021011140A2 (https=)
IL (1) IL285444A (https=)
MX (1) MX2021009440A (https=)
PE (1) PE20211709A1 (https=)
SG (1) SG11202106717PA (https=)
WO (1) WO2020163817A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2020163817A1 (en) * 2019-02-08 2020-08-13 Prothena Biosciences Limited Antibodies recognizing tau
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
AU2022306307A1 (en) * 2021-07-09 2024-02-01 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20250339553A1 (en) 2022-04-15 2025-11-06 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
JP2023175325A (ja) * 2022-05-30 2023-12-12 学校法人順天堂 タウオパチーの鑑別診断法
WO2025198916A1 (en) * 2024-03-16 2025-09-25 Abbvie Inc. Anti-tau antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7653100A (en) * 1999-09-09 2001-04-10 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. A minimal tau peptide for the nucleation of paired helical filaments
US8754034B2 (en) * 2009-02-06 2014-06-17 The Regents Of The University Of California Structure-based design of peptide inhibitors of amyloid fibrillation
NZ598356A (en) * 2009-07-30 2014-06-27 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
ES2656442T3 (es) 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
US9738709B2 (en) * 2011-10-21 2017-08-22 Ohio State Innovation Foundation Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
US9200068B2 (en) * 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
CA2902026C (en) * 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US20150253341A1 (en) * 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
EP4465050A3 (en) * 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
AU2016334051B2 (en) * 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
JP7165995B2 (ja) * 2017-02-21 2022-11-07 アールイーエムディー バイオセラピューティクス，インコーポレイテッド 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療
WO2020163817A1 (en) 2019-02-08 2020-08-13 Prothena Biosciences Limited Antibodies recognizing tau

Also Published As

Publication number Publication date
CO2021011140A2 (es) 2021-09-20
CN119954947A (zh) 2025-05-09
IL285444A (en) 2021-09-30
EP3921343A1 (en) 2021-12-15
JP7843068B2 (ja) 2026-04-09
CA3128392A1 (en) 2020-08-13
JP2025029046A (ja) 2025-03-05
PE20211709A1 (es) 2021-09-01
EP3921343A4 (en) 2022-12-14
CN113597431B (zh) 2025-02-21
MX2021009440A (es) 2021-09-10
JP7681316B2 (ja) 2025-05-22
AU2020219374A1 (en) 2021-07-01
CN113597431A (zh) 2021-11-02
BR112021015501A2 (pt) 2021-10-19
SG11202106717PA (en) 2021-07-29
WO2020163817A1 (en) 2020-08-13
US20220275067A1 (en) 2022-09-01
JP2022520672A (ja) 2022-03-31

Similar Documents

Publication Publication Date Title
JP7843068B2 (ja) タウを認識する抗体
US11584791B2 (en) Antibodies recognizing tau
JP7587304B2 (ja) タウ認識抗体
US11926659B2 (en) Antibodies recognizing tau
KR102533675B1 (ko) 타우 인식 항체
KR20210090184A (ko) 타우 인식 항체
CA3118818A1 (en) Antibodies recognizing tau
HK40120191A (zh) 识别tau的抗体
EA047155B1 (ru) Антитела, распознающие тау

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

D12-X000 Request for substantive examination rejected

St.27 status event code: A-1-2-D10-D12-exm-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000